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In systems biology, researchers aim to understand complex biological systems as a whole, which is often
achieved by mathematical modelling and the analyses of high-throughput data. In this review, we give an
overview of medical applications of systems biology approaches with special focus on hostepathogen
interactions. After introducing general ideas of systems biology, we focus on (1) the detection of putative
biomarkers for improved diagnosis and support of therapeutic decisions, (2) network modelling for the
identiﬁcation of regulatory interactions between cellular molecules to reveal putative drug targets and
(3) module discovery for the detection of phenotype-speciﬁc modules in molecular interaction networks.
Biomarker detection applies supervised machine learning methods utilizing high-throughput data (e.g.
single nucleotide polymorphism (SNP) detection, RNA-seq, proteomics) and clinical data. We demon-
strate structural analysis of molecular networks, especially by identiﬁcation of disease modules as a novel
strategy, and discuss possible applications to hostepathogen interactions. Pioneering work was done to
predict molecular hostepathogen interactions networks based on dual RNA-seq data. However, currently
this network modelling is restricted to a small number of genes. With increasing number and quality of
databases and data repositories, the prediction of large-scale networks will also be feasible that can used
for multidimensional diagnosis and decision support for prevention and therapy of diseases. Finally, we
outline further perspective issues such as support of personalized medicine with high-throughput data
and generation of multiscale hostepathogen interaction models. A. Dix, CMI 2016;22:600
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Systems biology aims at understanding and modelling complex
biological systems as a whole. Systems biology approaches may
focus on single or multiple levels, including genes, proteins, cells,
tissues, whole organisms or populations. This area of research has
emerged at the beginning of the 21st century [1e3]. It is charac-
terized by a strong connection of wet lab experiments and
computational analysis, where the analysis and modelling of
experimental data results in new hypotheses which lead to new
experiments [1].
Typically systems biology approaches are categorized into bot-
tom up and top down, where the bottom describes the interaction
of molecules and the top is the holistic view on the system. Bottom-11a, 07745 Jena, Germany
e).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).up approaches aim for elucidating the interactions of cell compo-
nents by submodel aggregation [4]. The view from the top is
created by genome-wide analysis and thus by the so-called omics
technologies (genomics, transcriptomics, proteomics, metab-
olomics) [5].
Microarrays and RNA sequencing (RNA-seq) are the two tech-
niques mainly used for transcriptome wide gene expression
analysis. In contrast to microarrays, RNA-seq has a higher sensi-
tivity in measuring genes with low abundances and allows the
identiﬁcation of novel transcripts as well as sequence variations
[6]. Moreover, RNA-seq facilitates expression analysis for non-
model organisms, including pathogenic microorganisms, since the
expensive step of manufacturing species-speciﬁc arrays is not
necessary. The analysis of proteomes at high sensitivity is facili-
tated by advances in mass spectrometryebased methods [7],
which superseded 2-D gel-based proteomics [8]. These methods
enable researchers to determine the quantity of proteins and
metabolites.of Clinical Microbiology and Infectious Diseases. This is an open access article under
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From a clinical perspective, systems biology of host cells, path-
ogen cells and their interaction with each other are of special in-
terest. In both players, these interactions result in the triggering of
signalling cascades, which may change the activity of proteins and
thus directly result in a phenotypic response. These changes
happen on different molecular levels and are quantiﬁed using
omics and image data, which computational analysis and model-
ling are challenging [9e11]. Often gene expression data are used, as
it gives a representative picture of the response of an organism to
an environmental change. In fact, gene expression data of either the
host or the pathogen during infection related conditions or in vivo
have strongly contributed to our knowledge about virulence fac-
tors, biomarkers, host immunity and dynamics of infection [12e14].
Going beyond the analysis of single-species transcriptomes, dual
trancriptomics simultaneously measure the gene expression of the
host and the pathogen during an infection. Here, processing and
measurement of transcript abundances of both host and pathogen
are performed simultaneously, while species-speciﬁc expression is
determined in silico [15,16]. There are a few examples where dual
transcriptomics were performed using dual microarray analysis
[17,18]. In addition, the advent of species-independent RNA-seq
platforms allows for high-quality dual RNA-seq [15,19].
Besides analyses restricted to the transcriptome, systems-level
approaches have been used to elucidate the virulence of microor-
ganisms like Salmonella [20e22], Yersinia pestis [23] or Mycobac-
terium tuberculosis [24]. These procedures also take metabolic
pathways and geneeprotein interactions into account. Multiple
databases have been set up to support the analysis of hostepath-
ogen interactions [9]. While some are speciﬁc to types of organisms
(e.g. bacteria or fungi) [25,26], others cover broader ranges of
pathogens and are only limited by the available data [27e29].Fig. 1. Overview of the relations of systems biology approaches for biomarker discovery, net
identiﬁed that indicate patient conditions and may serve as diagnostic or prognostic marke
regulatory networks are reconstructed. These networks predict novel molecular interaction
targets. The interaction network derived from prior knowledge forms the basis for the disco
and/or known associations between diseases and molecules. All three approaches require
knowledge for future experiments and analyses.Based on genome-scale metabolic modelling, analyses of the gut
microbiome have been performed, revealing interaction of the
microbial ecosystems, their interactions with the host and associ-
ations with disorders [30e34], also addressing symbiotic relation-
ships [35]. Recently the tool CASINO (Community And Systems-
level INteractive Optimization) has been developed, which allows
examination of microbeemicrobe, microbeehost and dietemic-
robe interactions based on metabolic modelling [36].
In systems biology, there are three widely accepted approaches
for the elucidation of key molecules and their interactions within
and between organisms (Fig. 1). First is the identiﬁcation of key
molecules, i.e. biomarkers, to monitor or predict disease progres-
sion and the condition of the host and thus ultimately support the
therapeutic decision making. Second is the network inference for
the identiﬁcation of relations between molecules, thereby uncov-
ering potential drug targets. Third is the identiﬁcation of disease
modules, i.e. groups of molecules and interactions associatedwith a
certain phenotype. In the following, we describe these approaches
in detail and provide exemplary ﬁndings in these research areas.
Biomarker Discovery
There are several deﬁnitions of biomarkers, which are discussed
by Strimbu and Tavel [37]. Some restrict biomarkers to application
areas like diseases, pathogenecity or pharmacology, while other
deﬁnitions are more general. Brieﬂy, a biomarker can be considered
as an objectivelymeasurablemedical sign that indicates a condition
or state. Biomarkers can be of any kind, including omics data, like
DNA/RNA sequences, proteins, mutations (SNPs) (Fig. 1) and other
attributes of an organism, e.g. an increased heart rate or body
temperature. With regard to hostepathogen interactions, bio-
markers can originate from both players. For example, the detec-
tion of the Aspergillus cell wall component galactomannan in thework inference and module discovery. With the help of omics data, biomarkers can be
r. Omics data are used for network inference, where, with support of prior knowledge,
s as well as important key regulatory molecules, which may become novel therapeutic
very of disease modules. Creation of hypotheses in this ﬁeld is supported by omics data
experimental validation of the generated hypotheses, which then serve as new prior
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supporting the diagnosis of invasive aspergillosis [38]. An example
for a host-speciﬁc marker is an increased procalcitonin level, which
is used as an indicator for bacterial infections, including sepsis [39].
Furthermore, procalcitonin correlates with the severity of the
infection and thus also serves as a prognostic biomarker for severe
sepsis and septic shock [40].
With respect to omics data, the techniques for the detection of
biomarkers are numerous. A common approach is the analysis of
differential regulation based on statistical signiﬁcance [41,42].
The required tools for this task are fast and well established.
However, this rather simple approach has some drawbacks.
Especially for large-scale quantiﬁcations (omics), the resulting set
of potential biomarkers may contain large redundancies and thus
also many false-positive ﬁndings. Therefore, subsequent valida-
tion experiments may be expensive, as more candidates have to
be veriﬁed. Moreover, this method does not consider combina-
torial effects. A more complex but promising approach is the
incorporation of machine learning techniques [43e46]. These
techniques comprise classiﬁcation and/or regression algorithms,
including, but not limited to, random forest [47], support vector
machines [48], k-nearest neighbours [49] and linear discriminant
analysis [50]. While the biomarker identiﬁcation using machine
learning methods requires a higher computational effort, they
often reduce the set of potential biomarkers to the most relevant
candidates. Additionally, some of them, e.g. random forest, take
interactions of variables into account, which means that combi-
natorial effects of biomarker candidates are considered [51].
The identiﬁcation of transcriptional biomarkers is of particularly
great interest because the regulation of gene expression reﬂects the
cellular response and the methods of measurement are well
established, fast and cost-effective. For example, gene signatures
that distinguish between latent and active tuberculosis [52] as well
as regulatory patterns to distinguish bacterial and fungal whole-
blood infections have been identiﬁed [44].
Apart from protein coding transcripts, another focus of the en-
deavours of biomarker discovery lies with noncoding RNAs
(ncRNAs), such as microRNAs (miRNAs) or Piwi-interacting RNAs
(piRNAs). Up to now, miRNAs are the best-investigated ncRNAs [53]
and have been successfully linked to infectious diseases such as
active tuberculosis [54], hepatitis B virus infections [55] and the
discrimination of the systemic inﬂammatory response syndrome
with sepsis [56].
Although transcriptional biomarkers can improve the diagnosis
and prognosis of infectious diseases, proteins represent the func-
tional level of gene expression, and thus they may better reﬂect
cellular responses. Therefore, they are the primary target point for
biomarker studies. The identiﬁcation of proteomic biomarkers,
however, is more complex. Proteins have a larger diversity as a
result of posttranslational modiﬁcations. Furthermore, they can
form multiprotein complexes, which may alternate the function of
the individual proteins. Nevertheless, there are successful advances
in infection biology. In tuberculosis research, protein biomarkers
were recently found that may allow tuberculosis diagnosis even in
immunocompromised patients [57].
Another area of biomarker analysis is the ﬁeld of genome-wide
association studies for SNP identiﬁcation. These studies aim to ﬁnd
connections between SNPs and disease phenotypes. Many SNPs in
protein coding regions are linked to severe health risks. SNPs also
have been associated with the susceptibility to infections and dis-
eases, like pneumonia in H1N1 inﬂuenza infection [58] or sepsis [59].
The connections between SNPs and diseases can be drawn using
DNA microarrays, which deliver the variant information of z1
million SNPs or more [60]. Due to the emergence of next-generation
sequencing, in particular DNA-seq, novel SNPs can be detected denovo, i.e. without a reference genome, allowing SNP detection at high
precision [61].
Molecular Network Modelling
In systems biology, the ultimate aim is to understand the mo-
lecular mechanisms underlying all biological processes on a sys-
tems level by means of mathematical modelling. These
mechanisms are commonly represented in a network composed of
nodes denoting molecules (e.g. proteins, DNA, RNA or metabolites)
and edges representing an interaction between the connected
nodes (e.g. proteineprotein, proteineDNA). One can distinguish
two broad areas in network science: ﬁrst, the generation and
structural analysis of interaction networks based on omics data
supported by prior knowledge (Fig. 1) and second, the integrated
analysis of interaction networks regarding the discovery of disease
associated modules supported by prior knowledge and omics data
(Fig. 1).
Automated inference of gene regulatory networks
With respect to mathematical modelling, a widely accepted
approach for the generation of interaction networks is the auto-
mated reverse engineering. Here, perturbations are used to change
the abundance of intracellular molecules, which is captured by
omics data. The model is then ﬁtted to the data, minimizing the
deviation between the predicted and the observed molecule
abundances. In the case of gene expression microarray or RNA-seq
data, these interaction networks are also termed gene-regulatory
networks (GRNs). Although the availability of omics data is
increased by decreasing costs, advancing standard operating pro-
cedures and reliability of the measurements in conjunction with
growing public data repositories, there are still central problems to
the automated inference of GRNs. Usually the number of available
measurements is much lower compared to the number of genes in
the mathematical model underlying the GRN. This results in an
underdetermined system with many equally good models. In gen-
eral, there is a relation between the complexity of the model in
terms of the number of free parameters per gene, the data required
to explain the observed systems behaviour and the quality of the
inferred GRN [62].
On the basis of this trade-off, a variety of approaches to the
inference of GRNs have been proposed. They can be roughly
grouped into two classes according to the number of genes inte-
grated in the ﬁnal network. On the one hand, there are approaches
for the inference of large-scale or even genome-wide networks.
These algorithms are computationally fast, using simpliﬁed, usually
static mathematical models that display either correlation between
genes predicting undirected edges (e.g. correlation-based algo-
rithms [63] and information theory-based algorithms [64e67]) or
causal relations among genes using weighted, directed edges (e.g.
regression-based algorithms [68e70]). The resulting large-scale
networks are usually used to study the topology of the network
graph. Quantiﬁable measures such as (1) node-degree distribution
[71], (2) betweenness centrality and (3) the clustering coefﬁcient
[72] give rise to (1) signal distributing hub genes, (2) central genes
with a large inﬂuence on the transfer of signals through the
network and (3) the underlyingmodular structure, respectively. For
example, network inference based on expression data of the human
pathogen Candida albicans was successfully applied for the identi-
ﬁcation of hub genes as new potential drug targets [73].
On the other hand, there are approaches for the inference of
small-scale networks. These algorithms use more sophisticated,
often dynamic mathematical models introducing biologically
relevant aspects, such as nonlinearity, in the relation between
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[74]. Common algorithms use models based on Boolean logic [75],
Bayesian networks [76], difference equation systems [77] and linear
[78] or nonlinear differential equation systems [79]. In the human
pathogenic fungus Aspergillus fumigatus, the inference of a dynamic
GRN was used to predict novel interactions between transcription
factors and target genes relevant for the regulation of iron ho-
meostasis [80].
Network inference has been mostly applied to predict GRNs of
either the host or the pathogen. However, the advent of dual tran-
scriptomics provides the possibility to infer molecular hostepath-
ogen interaction networks, giving rise to the molecular mechanisms
affected upon hostepathogen interaction [16]. In a pioneering study,
inference of the network underlying Candida albicans infection of
murine dendritic cells revealed two molecular hostepathogen in-
teractions indicating an interaction between the inﬂammatory re-
ceptor PTX3 and the fungal transcription factor HAP3, which were
experimentally validated [19].Network analysis uncovering disease modules
Recent advances in the ﬁeld of network science suggest the ex-
istence of disease modules in molecular networks, i.e. a group of
proteins residing in the same neighbourhood of the underlying
interaction network [81]. Several studies that identify modules un-
derlying diseases such as obesity and type 2 diabetes [82], asthma
[83] and inﬂammatory and malignant diseases [84] demonstrated
that the identiﬁed disease modules partially overlap, sharing mo-
lecular mechanisms as well as proteins. It was further shown that
the degree of overlap correlates with biological similarity, disease
symptoms and increased evidence of comorbidity [85]. The analysis
of disease modules, in conjunction with diverse data types (e.g.
genomics, genome-wide association studies, gene expression, gen-
eedisease association, clinically relevant information), has already
proven a successful strategy to the discovery of affected molecular
mechanisms, biomarkers and new drug targets as well as the
repositioning of drugs. For example, analysis of the disease module
underlying asthma revealed GAB1 signalling pathway as a novel
modulator of asthma and successfully linked the pathway to glu-
cocorticoids as a therapeutic agent [81]. In a study of breast cancer,
the combined use of an interaction network, disease-speciﬁc gene
expression data and patient survival data revealed a module
enriched in Aurora B signalling and kinetochore-associated genes,
whose expression was successfully validated to anticorrelate with
patient survival [86]. Translation of the concept of disease modules
on the hostepathogen relationship still remains problematic due to
a lack of genome-wide interaction networks comprising both host
and pathogen. Currently such models are restricted to gene subsets
[87] or describe gene islands [88,89].Outlook
Systems medicine
The analysis of hostepathogen interactions culminate in medi-
cal applications to improve diagnostics and therapies, thereby
increasing survival chances and reducing adverse effects. For this
aim, the results of systems biology studies have to be evaluated in
clinical trials. The focus on medical applications based on discov-
eries and methods of systems biology, including the creation of
associations between gene/protein behaviour to diseases and dis-
orders, is the topic of systems medicine [90e92]. This interdisci-
plinary approach aims to extend the spectrum of available
therapeutic and diagnostic molecules by systems-wide analysis.The analysis can be further enhanced by incorporating clinical
features, as shown by Reyes-Palomares et al. [93]. They combined
disease network models with pathophenotype data and thereby
found new connections between genes and diseases. This approach
can improve the understanding of the pathologic process and the
molecular mechanisms behind the host response. Moreover, a
comprehensive analysis of already known biomarkers to identify
associations to conditions different from the initial studies may
contribute to a broader knowledge and an extended range of ap-
plications. Increased levels of glycoprotein acetylation have been
determined as biomarker for incidence and mortality of cardio-
vascular disease [94,95]. In addition to this, Ritchie et al. [96]
discovered that these elevated levels serve as marker for
increased long-term risk of infection, especially septicaemia and
pneumonia. In conclusion, the identiﬁcation of biomarkers to
develop patient- and tissue-speciﬁc therapeutic solutions is one of
the key aspects in systems medicine [97]. Similarly, the elucidation
of interactions of genes and/or proteins by network analysis is
crucial to reveal disease processing [98].
Personalized medicine
The aim of personalized medicine is to improve individual
treatment and therapy in order to maximize beneﬁt and minimize
harm of patients [99]. The focus here is to account for patient-
individual characteristics, including molecular markers (e.g. ge-
netic markers). Thus, personalized medicine is strongly connected
to systems medicine research as the biomarkers are needed to
monitor the inﬂuence of a treatment to an individual. In fact, ge-
nomics, transcriptomics, proteomics andmetabolomics approaches
are of indispensable need to identify such biomarkers using unbi-
ased approaches [100].
As a result of rapidly decreasing costs of omics technologies,
especially in the ﬁeld of next-generation sequencing, there is no
long way to gain personal omics data of individuals at different
molecular levels. In fact, the dream of sequencing a human genome
for US$1000 is close to coming true [101]. Because most drug tar-
gets are proteins, the identiﬁcation and utilization of proteomic
markers is most common in clinical settings [102]. Therefore,
personalized medicine heavily relies on quantitative proteomics.
Frequently biomarker prediction is initiated by a genome-wide
transcriptomic screening based on microarray or RNA-seq. This
screening is followed by validation of selected genes using quan-
titative real-time PCR and quantiﬁcation of the proteins coded by
these genes (e.g. by Western blot test or ELISA). In some cases, the
validation of transcriptome-derived biomarkers on protein level
fails. Possible reasons are posttranscriptional and translational
regulations, protein modiﬁcations and different half-lives of pro-
teins and RNA. Comparing protein and RNA levels, a squared
Pearson correlation coefﬁcient ofz0.4 has been reported, showing
a moderate relation between the expression levels [103,104].
Therefore, the generation of proteomic data at large scale is of
particular importance for clinical studies.
The individual omics data allow two ways of application to
personalized medicine. Static personal and clinical information
(e.g. previous diseases) in combination with static biomarkers (e.g.
genetic markers) [105,106] will help to stratify the personal risk of
an individual gaining infection, suffering from a disease or
responding to a therapy. Furthermore, dynamic clinical data in
combination with dynamically changing biomarkers detected
from omics data will help support therapeutic decisions such as
the end of a therapy or when to change drug treatment. Moreover,
such dynamic biomarkers can predict the outcome of an infection.
One major research topic in system medicine will be the combi-
nation of biomarkers from multiple omics data together with
A. Dix et al. / Clinical Microbiology and Infection 22 (2016) 600e606604clinical biomarkers to ultimately improve predictions and diag-
nosis [100,107].
Translational system biology
Dynamic biomarkers are a starting point for ‘translational sys-
tems biology.’ This phrase was coined by Vodovotz and colleagues
[108,109] and describes the utilization of computer simulation to
optimize the design of drugs, as well as to simulate clinical trials
and the results of a therapy on individuals. Thus, translational
systems biology applies modelling and engineering approaches
with the aim of optimizing clinical practice [110]. Especially, the
extensive application of detailed mathematical modelling makes
translational systems biology a promising research area since they
not only predict a certain result but also contain information about
why this result is happening [111]. Thus, these models will give
clinicians a starting point for the change of a therapy. One partic-
ularly important direction of research is to set up models which are
not only built upon data from one (molecular) level but models
including data from different levels (i.e. molecular, tissue, organ,
whole body) [10]. Examples of success stories including multiscale
models are models which allow modulation of acute inﬂammation
[109], computer-optimized antibiotic treatment for tuberculosis
[112] and a novel mechanism for insulin resistance [113]. Also, in
this ﬁeld, the future task is to incorporate not only data from
different molecular or macromolecular levels in the model but also
personal data which may affect the system's response to stimuli via
differences in the initial conditions.
In summary, systems biology paved the way for the concept of
systems medicine (or ‘P4 medicine’dpredictive, preventive,
personalized and participatory) towards ‘precision medicine’ [114].
The integration of omics, clinical data and analysis of large patient
data sets has the potential to provide the basis for better molecular
understanding of diseases and as a consequence to design novel
and improved methods for diagnosis, prevention and therapy of
diseases [115].
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